Orchid vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE YC W23 AI clinical notes EHR for mental health therapists; $728K total ($500K YC seed Oct 2023) with HIPAA-compliant AI notes and EHR integration competing with SimplePractice for independent therapist documentation.
About
Orchid is a Wilmington, Delaware-based AI-powered EHR platform for mental health professionals — backed by Y Combinator (W23) with $728,000 in total funding including a $500,000 seed in October 2023 from Y Combinator — providing independent mental health clinicians (therapists, psychologists, counselors) with HIPAA-compliant AI clinical notes that integrate with any existing EHR, automating note-taking to free time for patient care. Launched Orchid AI in July 2024, with e-prescribing planned for 2025, Orchid streamlines the administrative workflows and clinical documentation burden that forces mental health professionals to spend 2-3 hours daily on paperwork that competes with patient care time. Founded in 2020, targeting the solo and small group independent mental health practice market.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies; processes millions of PA requests annually for specialty and retail prescriptions at no provider cost.
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.